Table 3.
Life expectancy and lifetime costs.
| Simplification strategy | ||||
|---|---|---|---|---|
| Base case | Standard of care | Without PI-resistant HIV | With PI-resistant HIV | Subjects with PI-resistant HIV, break-even % |
| Undiscounted life expectancy, years | 27.1 | 27.9 | 26.5 | 57.2 |
| Discounted life expectancy, years | 17.3 | 17.5 | 17.0 | 40.4 |
| Discounted QALE, years | 14.7 | 14.9 | 14.5 | 56.4 |
| Undiscounted lifetime cost, 2005 US$ | 760,300 | 731,200 | 646,300 | … |
| Undiscounted annual cost, 2005 US$ | 28,100 | 26,200 | 24,400 | … |
| Discounted lifetime cost, 2005 US$ | 456,700 | 430,200 | 384,300 | … |
| Sensitivity analyses | ||||
| Discounted QALE, years | ||||
| Decrease toxicity QOL effects by 50% | 14.8 | 14.9 | 14.6 | 38.2 |
| No NRTI toxicity benefit | 14.9 | 15.1 | 14.6 | 26.0 |
| Increase toxicity QOL effects by 50% | 14.5 | 14.8 | 14.4 | 71.2 |
| QOL effects of lipoatrophy and neuropathy continue for life | 14.4 | 14.7 | 14.4 | 85.9 |
| Discounted lifetime cost | ||||
| Monthly HIV RNA testing for first 6 months of simplification regimen | 456,700 | 430,600 | 384,800 | … |
| Monthly HIV RNA testing for duration of simplification regimen | 456,700 | 436,700 | 390,900 | … |
| Set cost of atazanavir-ritonavir equal to that of lopinavir-ritonavir | 440,500 | 379,400 | 350,700 | … |
NOTE. NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; QALE, quality-adjusted life expectancy; QOL, quality of life.